A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Table 5 CCV SAEs, n (%) (safety set)

	Glycopyrronium 50 μg o.d. (N = 327) n (%)	Tiotropium 18 μg o.d. (N = 330) n (%)
Patients with any serious CCV event	2 (0.6)	2 (0.6)
MACE	0	2 (0.6)
Non-fatal stroke	0	2 (0.6)
Non-major serious adverse cardiovascular events*	2 (0.6)	0

CCV = cardio- and cerebro-vascular; MACE = major cardiovascular adverse event; o.d. = once daily; SAE = serious adverse event; *Non-cardiac chest pain syndrome (n = 1), cardiac failure (n = 1).

ISSN: 1471-2466